Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a 3-Day course shift mental health care toward recovery?

NCT ID NCT05824234

Knowledge-focused Sponsor: Hôpital le Vinatier Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a 3-day training program called REFOCUS helps mental health teams provide care that supports personal recovery. About 760 people with severe mental disorders (like schizophrenia or bipolar disorder) will take part across 18 centers. Researchers will measure changes in patients' recovery progress and staff practices.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
REFOCUS training program (a 3-day course for mental health teams)
What this could lead to
If successful, this could show that training staff in recovery-oriented care improves patient outcomes and well-being.
What could go wrong
This is an early-stage implementation study, not a drug trial. Results depend on how well teams adopt the training, and benefits may vary across settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 760 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2023

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

15 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age from 15 to 65 years old. * Diagnosis of schizophrenia, schizoaffective disorder, schizotypal disorder and schizophreniform disorder or bipolar disorder, borderline personality disorder, disabling anxiety or depressive disorder (DSM-V criteria; APA, 2013). * Patients cared for by the team or unit benefiting from REFOCUS training * French mother tongue. * Patient affiliated or entitled to a social security scheme * Patient having received information about the study and having confirmed their participation in the study by signing the consent form * For minors (\< 18 years), information given to holders of parental authority and signature of consent. * For patients under curatorship, form signed by the patient and information given to the curator Exclusion Criteria: * Age less than 15 years old * Patients under guardianship * Presence of an associated intellectual disability * Neurological disorders of vascular, infectious or neurodegenerative origin. * Taking somatic drugs with a cerebral or psychic impact (eg corticosteroids).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bipolar disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anxiety disorder bipolar disorder borderline personality disorder depressive disorder major depressive disorder mental disorder psychiatric disorder schizoaffective disorder schizophrenia schizophreniform disorder schizotypal personality disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Mental disorders

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • centre de réhabilitation - Hôpital le Vinatier

    RECRUITING

    Lyon, Rhône, 69006, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.